Why invest in the veterinary market?

Veterinary medicine-a blooming market

The "humanization of pets" with owners willing to spend significantly on premium healthcare and pharmaceuticals and the increasing consolidation of the veterinary clinics, makes the veterinary pharmaceutical market a robust and promising sector. As the number of pets are steadily growing, so is the veterinary health market. The global pet medication market is anticipated to grow at an annual rate of 7.2% between 2025 and 2031. These projections are supported by the rapid growth seen on the European pet medication market from EUR 2.7 billion to EUR 4.4 billion between 2019 and 2024 (CAGR of 10.3%) and from the U.S. market which grew by 40% from EUR 7.7 billion (USD 9 billion) to EUR 10.7 billion (USD 12.6 billion) between 2018 and 2024. The absence of a prescription drug specifically for weight management in companion animals represents a significant and untapped opportunity within this dynamic market.

Development costs for human vs. veterinary drugs

Human Medicine (10–15 years, $1 billion+) The process is prolonged by extensive multi-phase clinical trials (Phases I, II, III), rigorous safety testing, and larger regulatory hurdles. The enormous costs are driven by the sheer scale of clinical trials, massive data requirements, and the high rate of failure in late-stage trials.

Veterinary Medicine - for companions (5–10 years, $20–$50 million): Veterinary drug development is often expedited compared to human medicine, sometimes beginning at what would be considered Phase III in human trials. Pivotal clinical trials for animals often require only a few hundred patients, compared to thousands for humans. While still expensive, veterinary drugs are much cheaper to develop because of fewer, smaller clinical trials. Veterinary studies often focus on target animal effectiveness, rather than the multi-phase, multi-year progression required for human drugs.

Want to join our journey?

Prodessa Pharmaceuticals is looking for partners and investors

We are currently in search of collaborators, both academic and commercial, as well as funding from diverse sources, including angel investors, public funding, and private equity.

· Seed capital for drug development and testing

· Drug development and production partners

· Preclinical and clinical trials partners

· Funding for expanding in-house research capabilities to develop next-generation SHIP inhibitors

· Partners for broader testing in overweight models and additional disease indications

As the company grows, we aim to strengthen the internal R&D to accelerate innovation and diversify therapeutic applications.

Why invest in the veterinary market?

Veterinary medicine-a blooming market

Development costs for human vs. veterinary drugs

Want to join our journey?

Prodessa Pharmaceuticals is looking for partners and investors

Prodessa Pharmaceuticals

This website uses cookies.